ERBB2 and gastric cancer: However, most patients with advanced HER2 gene-amplified gastric cancer eventually relapse after treatment, suggesting that tumors acquire or intrinsically possess mechanisms to escape from HER2 inhibition, necessitating other strategies to control HER2-positive gastric cancer8,9.